HWHG(SH:600079) Xin Lang Cai Jing·2026-02-26 00:06Core Viewpoint - After completing a significant restructuring, Renfu Pharmaceutical (600079.SH) has received strong support from its new controlling shareholder,招商生命科技 (招商生科), which plans to raise between 3 billion to 3.5 billion yuan through a private placement to fund innovative drug research and manufacturing upgrades [1][2]. Group 1: Fundraising and Investment Plans - The company intends to issue shares to招商生科, with the net proceeds aimed at various projects including innovative drug research, a manufacturing base for complex formulations, and digital transformation initiatives [2][3]. - The share issuance price is set at 14.95 yuan per share, with a total issuance of no less than 200 million shares and no more than 234 million shares, not exceeding 30% of the total share capital prior to the issuance [2]. - Specific allocations include 1.042 billion yuan for the Yichang Renfu project focusing on new central nervous system drugs, 639 million yuan for the headquarters research institute project, 790 million yuan for the sexual health and complex formulations manufacturing base, and 212 million yuan for digital construction [2][3]. Group 2: Company Background and Performance - Renfu Pharmaceutical was established in 1993 and listed on the Shanghai Stock Exchange in 1997, with core products including anesthetic drugs [4]. - The previous major shareholder, Wuhan Contemporary Technology Industry Group, faced a debt crisis leading to a decline in Renfu's profits from 2.484 billion yuan in 2022 to 1.33 billion yuan in 2024 [5][6]. - Following the restructuring,招商局集团 became the core strategic investor, injecting 11.8 billion yuan and gaining control over Renfu's shares, which has led to a recovery in performance with a net profit of approximately 1.689 billion yuan in the first three quarters of 2025, a year-on-year increase of 6.22% [6][7]. Group 3: Future Outlook - The company aims to achieve over 27 billion yuan in revenue for the full year, with a gross margin target of 45%, positioning itself as a leader in the industry [7]. - Despite facing a temporary suspension of trading due to previous shareholder issues, the new controlling shareholder's support is expected to facilitate a return to normal operations by late 2026 or early 2027 [7].